The FDA approved the cholesterol-lowering injection Praluent Friday. The drug can be administered by patients themselves, and costs around $15,000 a year. The same committee that recommended Praluent to FDA has also recommended another drug that serves the same purpose, Repatha, still up for final approval by the FDA.
